Exscientia vs Lunit

Lunit has a disclosed valuation of $829M, while Exscientia's valuation is not publicly available, making a direct size comparison difficult. Lunit employs 300 people.

Exscientia has raised more in total funding at $500M, compared to Lunit's $150M — a gap of $350M. Combined, the two companies have completed 4 known funding rounds.

Exscientia holds the higher Awaira Score at 72/100, compared to Lunit's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 9-point gap that reflects meaningful differences in scale or traction.

Exscientia was founded by Andrew Hopkins in 2012. Lunit was founded by Brandon Suh in 2013. Visit each company's profile on Awaira for a full founder biography.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. Lunit: Lunit is a South Korean AI healthcare company founded in 2013 that specializes in diagnostic imaging analysis using artificial intelligence. The company develops machine learning algorithms designed to assist radiologists in detecting abnormalities across medical imaging modalities, particularly in chest radiography, breast cancer screening, and CT scans. Lunit's core platform uses deep learning to analyze medical images and provide clinical decision support, aiming to improve diagnostic accuracy and efficiency in healthcare settings. The company's primary products include Lunit INSIGHT, a software solution that integrates with existing hospital infrastructure and picture archiving systems. Lunit has established a presence across Asia, Europe, and other regions, with its technology deployed in hospitals and diagnostic centers. The company went public on the Korean stock exchange, achieving a valuation of $0.8 billion. With $150 million in total funding raised through various rounds before its public listing, Lunit operates in a competitive segment alongside companies like Zebra Medical Vision, Arterys, and various regional competitors. The company faces competition from both specialized AI diagnostic firms and larger healthcare technology providers developing similar capabilities. Lunit's growth trajectory reflects increasing adoption of AI in medical imaging across Asia-Pacific markets, where regulatory pathways and healthcare infrastructure continue to evolve to accommodate such technologies. Lunit is among the few AI medical imaging companies to achieve public market status, particularly from South Korea, reflecting regional strength in healthcare technology innovation.

Exscientia was founded first in 2012, giving it 1 year of additional market experience. Lunit was founded later in 2013. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Exscientia has approximately 100-500 employees, while Lunit has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Exscientia and Lunit are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.